New Delhi: US-based Advent could rope in new investors into its planned combination of Suven Pharma and Cohance Life Sciences, as it looks to create a top three contract development and manufacturing organisation with a diversified shareholder base by combining the portfolio companies, according to sources in the know.'A few investors have been sounded out.

新德里：美国的出现可能会促使新投资者参与其计划中的Suven Pharma和Cohance Life Sciences的组合，因为它似乎通过组合公司创建了一个拥有多元化股东基础的前三大合同开发和制造组织，根据来源于知道“一些投资者已经发出声音。

They are looking to induct new investors as part of the merger plan of Suven Pharma with Cohance. The idea is to have a diversified shareholder base in the merged entity and bring in investors who could add value to the business,' a person in the know said.Enhance Your Healthcare Expertise with High-Impact CoursesOffering CollegeCourseWebsiteIIM KozhikodeIIMK Healthcare Management & Analytics ProgrammeVisitIndian School of BusinessISB Healthcare ManagementVisitThe merger is still on the drawing board, the sources cautioned.The US PE firm completed its ₹6,313-crore acquisition of Suven Pharma on Friday wherein it has acquired 50.1% stake in the company from the past promoters and will make an open offer for a further 26% stake.

他们希望招募新投资者作为Suven Pharma与Cohance合并计划的一部分。这个想法是在合并的实体中建立多元化的股东基础，并聘请可以为企业增加价值的投资者，“知情人士说。通过高影响力的课程提高您的医疗保健专业知识提供大学课程网站KozhikodeIIMK医疗保健管理与分析计划在美国商业学院医疗保健管理访问合并仍在绘图板上，消息来源警告说。美国体育公司完成了₹6313 crore于周五收购Suven Pharma，其中已从过去的发起人那里收购该公司50.1%的股份，并将进一步公开收购26%的股份。

It also owns a majority stake in Cohance Life Sciences, an active pharmaceutical ingredient (API) manufacturer that was put together by combining three companies - RA Chem Pharma, Avra Labs and ZCL Chemicals - all of which were acquired in the past three years and are unlisted.'They expect good investor acceptance of Suven Pharma's open offer.

它还拥有Cohance Life Sciences的大部分股份，Cohance Life Sciences是一家活性药物成分（API）制造商，由三家公司（RA Chem Pharma，Avra Labs和ZCL Chemicals）合并而成-所有这些公司都是在过去三年中收购的未上市“他们期望Suven Pharma的公开报价得到良好的投资者接受。

That could make them a very significant shareholder of the company,' one of the people said.Details about the quantum of stake Advent could sell in the Suven Pharma-Cohance combined entity and the value of that stake are still being determined, as per the sources.'There is no outreach being made to financial investors,' Advent said in its response to ET's.

其中一人说，这可能会使他们成为公司非常重要的股东。有关股份数量出现的详细信息可能会在Suven Pharma Cohance合并实体中出售，并且该股份的价值仍在确定中“金融投资者没有任何联系，”Advent在回应ET时表示。